Fractyl Health 8-K: Exit Activities & Financials

TL;DR

Fractyl Health filed an 8-K on Jan 31, 2025, detailing exit activities and financial exhibits.

AI Summary

Fractyl Health, Inc. filed an 8-K on January 31, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and financial statements and exhibits. The filing does not contain specific dollar amounts or detailed descriptions of the exit or disposal activities.

Why It Matters

This filing indicates potential restructuring or divestiture activities within Fractyl Health, which could impact future operations and financial performance.

Risk Assessment

Risk Level: low — The filing is procedural and lacks specific financial or operational details that would indicate immediate high risk.

Key Players & Entities

• FRACTYL HEALTH, INC. (company) — Registrant
• January 31, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 3 Van de Graaff Drive Suite 200 (address) — Principal Executive Office Address
• Burlington, Massachusetts (location) — Principal Executive Office Location

FAQ

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share GUTS The Nasdaq
• $1.8 million — ill incur cash charges of approximately $1.8 million related to severance, employee benefits

Filing Documents

• guts-20250131.htm (8-K) — 62KB
• guts-ex99_1.htm (EX-99.1) — 28KB
• 0000950170-25-011430.txt ( ) — 216KB
• guts-20250131.xsd (EX-101.SCH) — 25KB
• guts-20250131_htm.xml (XML) — 5KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 31, 2025, Fractyl Health, Inc. (the "Company") approved a strategic reprioritization (the "Strategic Reprioritization"), pursuant to which the Company intends to: prioritize its REMAIN-1 pivotal study, a randomized, double-blind study of Revita, the Company's lead product candidate, versus sham in patients who have lost at least 15% total body weight on tirzepatide therapy; advance Rejuva, the Company's novel, locally administered, adeno-associated virus delivered pancreatic gene therapy platform, into first-in-human studies; and pause investment in Revita programs for type 2 diabetes, consisting of the REVITALIZE-1 study and the German Real-World Registry. The Strategic Reprioritization was driven by positive preliminary data from the REVEAL-1 study, which is an open-label cohort of the REMAIN-1 study, strong demand for participation in the REMAIN-1 study, and strong patient and physician feedback on the need for durable weight maintenance solutions. As part of the Strategic Reprioritization, the Company is streamlining resources, including a workforce reduction impacting 22 employees, or approximately 17% of the Company's workforce. The Company anticipates the Strategic Reprioritization will be substantially implemented by the second quarter of 2025. In connection with the Strategic Reprioritization, the Company estimates that it will incur cash charges of approximately $1.8 million related to severance, employee benefits, and other related personnel reduction costs. At this time, the Company is unable in good faith to make a determination of other estimated costs, if any, associated with the Strategic Reprioritization due to unknown potential contract termination costs, if any, regarding which the Company is performing an ongoing assessment. The Company intends to amend this Current Report on Form 8-K within four business days of when it is able to estimate these additional cost

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 31, 2025, the Company issued a press release announcing the Strategic Reprioritization. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our anticipated financial performance, including cash and cash equivalents, for any period of time, the Strategic Reprioritization, including its implementation and the expected costs and benefits, if any, the promise and potential impact of our preclinical or clinical trial data, the design, initiation, timing and results of clinical enrollment and any clinical studies or readouts, the content, information used for, timing or results of any IND-enabling studies, IND applications or Clinical Trial Applications, the potential launch or commercialization of any of our product candidates or products, the potential treatment population or benefits for any of our product candidates or products, our strategic and product development objectives and goals, and the timing of any of the foregoing. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the Company's limited operating history; the incurrence of significant net losses and the fact that the Company expects to continue to incur significant net losses for the foreseeable future; the Company's need for substantial additional financing; the Company's ability to continue as a going concern; the restrictive and financial covenants in the Company's credit agreement; the lengthy and unpredictable regulatory approval

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d)Exhibits The following exhibit relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Fractyl Health, Inc. Press Release dated January 31, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fractyl Health, Inc. Date: January 31, 2025 By: /s/ Harith Rajagopalan Harith Rajagopalan, M.D., Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR